

FORM PTO 1449 (modified)		Atty. Docket No. X-10242A		Serial No 09/997,792		10971 U.S. PTO 09/997792  11/30/01		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Ronald Norbert Hermeling, et al.						
		Filing Date 11-30-2001		Group 1653				
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate		
JRL	AA	5,120,712	06/09/92	Habener, J.	514	12		
JRL	AB	5,118,666	06/02/92	Habener, J.	514	12		
JRL	AC	5,545,618	08/13/96	Buckley, D.	514	12		
JRL	AD	5,705,483	01/06/98	Galloway, J.	514	12		
JRL	AE	5,512,549	04/30/96	Chen, V.	514	12		
JRL	AF	5,734,026	03/31/98	Florin-Robertsson	530	424		
JRL	AG	5,780,599	07/14/98	Junker, et al.	530	399		
JRL	AH	5,977,071	11/02/99	Galloway	514	12		
	AI							
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
	BA	EP 619322	03/13/96	EPO				
JRL	BB	WO 95/05848	03/02/95	PCT				
JRL	BC	WO 93/25579	12/23/95	PCT				
JRL	BD	WO 98/19698	05/14/98	PCT				
JRL	BE	WO 98/08871	03/05/98	PCT				
JRL	BF	WO 97/15296	05/01/97	PCT				
JRL	BG	WO 96/20005	07/04/96	PCT				
JRL	BH	WO 98/20895	05/22/98	PCT				
JRL	BI	EP 0869135	10/07/98	EPO				
EXAMINER Jeffrey E. Russel				DATE CONSIDERED May 28, 2002				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								

FORM PTO 1449 (modified)				Atty. Docket No. X-10242A		Serial No 07/997,792	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Applicants Ronald Norbert Hermeling, et al.			
				Filing Date 11-30-2001		Group 1653	
JR	BJ	EP 0658568	06/21/95	EPO			
JR	BK	EP 0619322	10/18/94 12	EPO			
	BL						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
JR	CA		Komatsu, R., et al., Diabetes, 38:902-905, 1989.				
JR	CB		Orskov, C., et al., J. Biol. Chem., 264(22):12826-12829, 1989.				
JR	CC		Majsov, S., Int. J. Peptide Protein Res., 40:33-343, 1989.				
JR	CD		Holz, G. G., et al., Nature, 361:362-365, 1993.				
JR	CE		Orskov, C., Diabetologia, 35:701-711, 1992.				
JR	CF		Mentlein, R., et al., Eur. J. Biochem., 214:829-835, 1993.				
JR	CG		Nauck, M. A., et al., J. Clin. Invest., 91:301-307, 1993.				
JR	CH		Nauck, M. A., et al., Diabetologia, 36:741-744, 1993.				
JR	CI		Gutniak, M., et al., N. E. J. Med., 326(20):1316-1322, 1992.				
JR	CJ		Thorens, B., et al., Diabetes, 42:1219-1225, 1993.				
JR	CK		Suzuki, S., et al., Endocrinology, 125:3109-3114, 1990.				
JR	CL		Ananthanancayanan, V. V., et al., Mol. Biol. Cell (Supp), 3, 250A, #1452, 1992.				
JR	CM		Epand, R. M., Mol. Pharmacol., 22:105-108, 1982.				
JR	CN		Kim, Y., et al., Pharm. Res., 12:1664-1670, The Application of Crystal Soaking Technique to Study the Effect of Zinc and Cresol on Insulinotropin Crystals Grown from a Saline Solution, 1995.				
JR	CO		Naslund, E., et al., Drug News Perspect, 11:92-97, 1998.				
JR	CP		Naslund, E., et al., Am. J. Clin. Nutr., 68:525-530, 1998.				
JR	CQ		Flint, A., et al., J. Clin. Invest., 101:515-520, 1998.				
JR	CR		Lone Pridal, et al., International Journal of Pharmaceutics, 136:53-59, Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine, 1996.				
EXAMINER Jeffrey E. Russell				DATE CONSIDERED Dec 28, 2002			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							